Used in the treatment of chronic myeloid leukemia (CML), particularly in patients resistant to other therapies. It works by inhibiting protein synthesis in cancer cells, leading to cell cycle arrest and apoptosis. Clinical studies support its effectiveness in inducing remission in both chronic and accelerated phases of CML. Also under investigation for use in acute myeloid leukemia (AML) and other hematologic malignancies due to its potent anti-leukemic activity. Administered intravenously under medical supervision due to its narrow therapeutic index and potential toxicity.